← Back to all grants

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Funding
See details
Status
Closing soon
Deadline
September 30, 2026 (18 days left)
Agency
Scope
Nationwide
Source
Grants.gov
Est. $12M total
September 30, 2026 (18 days left)
Nationwide

Description

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Eligibility

See official grant page for eligibility requirements

Industry Tags

Healthcare

About This Grant

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Funding Information

Estimated Total Program Funding
$12,000,000
Expected Number of Awards
6

Eligibility Overview

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.

Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:

  • Nonprofits and 501(c)(3) organizations
  • Small businesses and startups (especially for SBIR/STTR programs)
  • State, local, and tribal governments
  • Colleges, universities, and research institutions
  • Individuals (for select programs in education, arts, and research)

Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.

How to Apply

  1. 1

    Review the full opportunity

    Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362196).

  2. 2

    Confirm eligibility

    Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.

  3. 3

    Prepare required documents

    Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.

  4. 4

    Submit before the deadline

    This opportunity closes on September 30, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.

Grant Writing Tips

Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:

  • Start your application at least 4 weeks before the deadline — rushed proposals score lower.
  • Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
  • Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.

More Grants from Defense Health Agency Contracting Activity - DHACA

Frequently Asked Questions

Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award?

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.

How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award provide?

The total estimated program funding for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is $12,000,000.

When is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award?

The application deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is September 30, 2026. Submit at least 48 hours early to avoid last-minute portal issues.

How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award?

Apply for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award through the official grant page (https://www.grants.gov/search-results-detail/362196). Confirm your eligibility and prepare your application materials before the deadline.

Helpful Resources

✍️Grant Writing Help

Need help writing your grant application?

Try Instrumentl — Grant Writing Software →
🏢Start Your Business

Need to form an LLC or corporation first?

Form your business with ZenBusiness →
🤝Nonprofit Formation

Starting a nonprofit to apply for grants?

Launch your nonprofit with Swyft Filings →
📊Grant Management

Track and manage multiple grant applications?

Try Bloomerang for nonprofits →

GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.

Related Grants